Samsung Biologics Co Ltd (207940) — Long-term Investment Intensity
Samsung Biologics Co Ltd (207940) has a Long-term Investment Intensity of 43.2% as of December 2018. Long-term investments of ₩2.59 Trillion represent 43.2% of total assets of ₩5.98 Trillion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Samsung Biologics Co Ltd (207940) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Samsung Biologics Co Ltd Long-term Investment Intensity (2014–2018)
This chart shows how Samsung Biologics Co Ltd's Long-term Investment Intensity has evolved across 5 annual periods from 2014 to 2018. As of December 2018, the intensity stands at 43.2%, reflecting long-term investments of ₩2.59 Trillion against total assets of ₩5.98 Trillion KRW. Explore Samsung Biologics Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Samsung Biologics Co Ltd (2014–2018)
The table below presents the year-by-year Long-term Investment Intensity for Samsung Biologics Co Ltd from 2014 to 2018, covering 5 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see Samsung Biologics Co Ltd market cap and net worth.
| Year | LT Investment Intensity | LT Investments (KRW) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2018 | 43.2% | ₩2.59 Trillion | ₩5.98 Trillion | ▼ -26.5 pp |
| 2017 | 69.7% | ₩5.01 Trillion | ₩7.18 Trillion | ▲ +4.1 pp |
| 2016 | 65.6% | ₩4.94 Trillion | ₩7.53 Trillion | ▼ -15.5 pp |
| 2015 | 81.2% | ₩4.84 Trillion | ₩5.96 Trillion | ▲ +77.2 pp |
| 2014 | 4.0% | ₩53.92 Billion | ₩1.36 Trillion | — |